Solventum Co. (NYSE:SOLV) Stake Reduced by Focus Financial Network Inc.

Focus Financial Network Inc. decreased its holdings in shares of Solventum Co. (NYSE:SOLV) by 11.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,980 shares of the company’s stock after selling 1,526 shares during the period. Focus Financial Network Inc.’s holdings in Solventum were worth $791,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Trian Fund Management L.P. lifted its stake in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. State Street Corp lifted its position in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after acquiring an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Solventum during the 3rd quarter worth $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Solventum by 0.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock worth $73,469,000 after acquiring an additional 3,745 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Piper Sandler upped their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Price Performance

NYSE SOLV opened at $73.62 on Thursday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a 50 day simple moving average of $70.51 and a 200-day simple moving average of $68.32. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.